EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Vascular burden attenuates the TDP-43-TMEM106B pathological relationship in neurodegenerative disease with and without Alzheimer disease neuropathological change

Vaskuläre Belastung schwächt die pathologische Beziehung zwischen TDP-43 und TMEM106B bei neurodegenerativen Erkrankungen mit und ohne Alzheimer-Krankheits-Neuropathologie

Matthew B Dopler iD, Cole Corbett, Angelique D Gonzalez, Ali Ghaseminejad-Bandpey, Mallory Keating, Kyra M Clarke, Oluwaseun B Ogunbona, Gladys Maestre, Sudha Seshadri, Shahroo Etemadmoghadam, Margaret E Flanagan iD

Journal of Neuropathology & Experimental Neurology · 01.09.2026 · 85 (9) · 963-974

DOI: 10.1093/jnen/nlag031 ↗

Auf einen Blick

In postmortalen Hippocampus-Proben war TMEM106B vor allem mit Alter und weiblichem Geschlecht assoziiert. Eine höhere vaskuläre Belastung schwächte die positive Beziehung zwischen TDP-43 und TMEM106B.

Fragestellung

Wie hängen TMEM106B, TDP-43, Alzheimer-Krankheits-Neuropathologie und zerebrovaskuläre Erkrankung im menschlichen Hippocampus zusammen?

Methode

Postmortale humane Hippocampus-Analyse mit digitaler Pathologie; lineare Regressionsmodelle. Fälle mit verschiedenen ADNC-Grade und sekundär nach TDP-43-Positivität sowie CVD-Schwere stratifiziert.

Ergebnisse

Alter und weibliches Geschlecht waren unabhängige Prädiktoren der TMEM106B-Immunopositivität. Braak-Stadium, CERAD-NP-Score und Thal-Phase waren nicht assoziiert. Die positive TDP-43-TMEM106B-Assoziation nahm mit höherer CVD-Schwere ab.

Einschränkungen

Sensitivitätsanalysen nur bei LATE-NC schwächten mehrere Assoziationen ab; gepoolte TDP-43-Befunde sollten vorsichtig interpretiert werden.

Schlussfolgerung der Autor:innen

TMEM106B-Immunreaktivität war am stärksten mit Alter und Geschlecht assoziiert; die vaskuläre Belastung modifizierte ihre Beziehung zur TDP-43-Proteinopathie.

Kernaussagen

  • TMEM106B war vor allem mit Alter und weiblichem Geschlecht assoziiert.
  • Braak, CERAD-NP und Thal zeigten keine unabhängige Assoziation.
  • Mehr CVD-Pathologie schwächte die TDP-43-TMEM106B-Beziehung ab.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, online erschienen am 17.04.2026. Verfasst von Matthew B Dopler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, Unit…. Hauptthemen laut MEDLINE: Alzheimer Disease, DNA-Binding Proteins, Nerve Tissue Proteins, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH HHS, NCATS NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TMEM106B, a lysosomal transmembrane protein, is a risk factor for neurodegenerative diseases, including Alzheimer disease (ad) and TDP-43 proteinopathies. TMEM106B pathology occurs in normal aging and is increased in TDP-43 proteinopathy but its role in dementia remains unclear. Cerebrovascular disease (CVD) is a driver and co-pathology of dementia, yet its contribution to TMEM106B accumulation in the context of TDP-43 and ad neuropathological changes (ADNC) has not been explored. We analyzed post-mortem human hippocampal sections spanning not-, low-, intermediate-, and high-ADNC. In secondary analyses, cases ≥65 years were stratified by TDP-43 immunopositivity and CVD severity; cases <65 years were included to contextualize age-associated effects. TMEM106B immunoreactivity was quantified using digital pathology. Linear regression models demonstrated that age and sex (higher in females) were independent predictors of TMEM106B immunopositivity whereas Braak stage, CERAD-NP score, and Thal phase were not. The positive TDP-43-TMEM106B association was attenuated with increased CVD pathology severity, suggesting that vascular burden modifies this relationship. Sensitivity analyses restricted to LATE-NC attenuated several associations, indicating that pooled TDP-43 findings should be interpreted cautiously given possible disease heterogeneity. TMEM106B immunoreactivity was most strongly associated with age and sex, while vascular burden, rather than ADNC level, modified its relationship with TDP-43 proteinopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDNA-Binding ProteinsNerve Tissue ProteinsMembrane ProteinsCerebrovascular DisordersHippocampusNeurodegenerative DiseasesHumansFemaleMaleAgedAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

Alzheimer diseaseTDP-43TMEM106Bcerebrovascular disease

Substanzen

DNA-Binding ProteinsNerve Tissue ProteinsTARDBP protein, humanTMEM106B protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
  • Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
  • Institute of Neurosciences, School of Medicine, University of Texas Rio Grande Valley, Harlingen, TX, United States.
  • Rio Grande Valley Alzheimer's Disease Resource Center for Minority Aging Research (RGV AD-RCMAR), University of Texas Rio Grande Valley, Brownsville, TX, United States.
  • Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, TX, United States.

ORCID-Profile: Matthew B Dopler, Margaret E Flanagan

Förderung

  • NIA NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS
  • Owen's Foundation Grant and the Baptist Foundation of San Antonio Endowment
  • National Institutes of Health
  • Owen’s Foundation Grant and the Baptist Foundation of San Antonio Endowment

Zitieren

APA

Dopler, M. B., Corbett, C., Gonzalez, A. D., Ghaseminejad-Bandpey, A., Keating, M., Clarke, K. M., Ogunbona, O. B., Maestre, G., Seshadri, S., Etemadmoghadam, S., & Flanagan, M. E. (2026). Vascular burden attenuates the TDP-43-TMEM106B pathological relationship in neurodegenerative disease with and without Alzheimer disease neuropathological change. Journal of Neuropathology & Experimental Neurology, 85(9), 963-974. https://doi.org/10.1093/jnen/nlag031

Vancouver

Dopler MB, Corbett C, Gonzalez AD, Ghaseminejad-Bandpey A, Keating M, Clarke KM, et al. Vascular burden attenuates the TDP-43-TMEM106B pathological relationship in neurodegenerative disease with and without Alzheimer disease neuropathological change. Journal of Neuropathology & Experimental Neurology. 2026;85(9):963-974. doi:10.1093/jnen/nlag031

BibTeX
@article{Dopler2026,
  author = {Dopler, Matthew B and Corbett, Cole and Gonzalez, Angelique D and Ghaseminejad-Bandpey, Ali and Keating, Mallory and Clarke, Kyra M and Ogunbona, Oluwaseun B and Maestre, Gladys and Seshadri, Sudha and Etemadmoghadam, Shahroo and Flanagan, Margaret E},
  title = {Vascular burden attenuates the TDP-43-TMEM106B pathological relationship in neurodegenerative disease with and without Alzheimer disease neuropathological change},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2026},
  volume = {85},
  number = {9},
  pages = {963--974},
  doi = {10.1093/jnen/nlag031}
}
Kostenlos starten →